AN2 Therapeutics (ANTX) Other Non Operating Income (2021 - 2024)

AN2 Therapeutics (ANTX) has 4 years of Other Non Operating Income data on file, last reported at $1.3 million in Q3 2024.

• Other Non Operating Income for Q3 2024 came in at $1.3 million, down 13.99% year-over-year; the trailing twelve-month figure through Dec 2024 was $1.3 million (up 2848.84% YoY), and the FY2025 annual result was $1000.0, changed 0.0% from the prior year.
• Other Non Operating Income rose to $1.3 million in Q3 2024 per ANTX's latest filing, from $1000.0 in the prior quarter.
• Over five years, Other Non Operating Income peaked at $1.5 million in Q3 2023 and troughed at -$2.9 million in Q4 2023.
• A 4-year average of $198384.6 and a median of $213000.0 in 2022 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2022 and 2023: Other Non Operating Income jumped 2781.82% in 2022, then sank 564.2% in 2023.
• A 4-year view of Other Non Operating Income shows it stood at $22000.0 in 2021, then jumped by 2781.82% to $634000.0 in 2022, then slumped by 564.2% to -$2.9 million in 2023, then jumped by 143.05% to $1.3 million in 2024.
• Business Quant data shows ANTX's Other Non Operating Income at $1.3 million in Q3 2024, $1000.0 in Q1 2024, and -$2.9 million in Q4 2023.